Abstract:Abstract Introduction: This work presents the characterization of two novel HER2 targeting peptides to measure which has the most compatible properties to be used as a siRNA carrier to knock down the CD44 gene in HER2+ breast cancer. Procedures: Targeting peptides were electrostatically complexed with non-targeting siRNAs at different N:P ratios to determine the minimum binding ratios needed to form nanoparticles. Different ratios of peptide-siRNA complexes were tested to determine the minimum molar ratio at which the peptides would protect siRNA from degradation. Cytotoxicity assays were performed to determine cytotoxicity levels at different peptide concentrations. Dynamic light scattering assay was performed to determine peptide-siRNA nanoparticle size and zeta potential. Immunofluorescent microscopy was used to determine the targeting of the peptide to HER2+ cells compared to cells not expressing HER2. Summary of Results: Peptide-siRNA complexes for the P51 and P25 peptides formed at a minimum 20:1 N:P ratio. P25 and P51 peptides both successfully protects the siRNA at N:P ratios from 20:1 to 60:1 for both degradation agents. Cytotoxicity assays show that in the SKBR3 cell line, the P25 and P51 peptides both showed above 80% viability until the 70:1 ratio; however, in the BT474 cell line, the P25 showed above 80% viability to the 50:1 ratio, but the P51 was only viable in the 20:1 ratio. The results of these studies illustrate how both peptides protect siRNA but that the P51 peptide is toxic to some HER2+ breast cancer cell lines. Conclusions: Results show that both peptides target HER2+ breast cancer and are compatible carriers of siRNA, protecting the siRNA well within a cell-like environment. However, from MTS studies, P25 appears less cytotoxic to the cell lines than P51, which shows higher cytotoxicity at high molar ratios. We observed that the P25 protects siRNA from degradation, is cytocompatibility, and promotes efficient internalization into HER2+ cell lines. Future work will include the development of a tandem peptide, including a targeting peptide fused with a fusogenic peptide to increase cancer targeting and efficacy of this targeted treatment. Acknowledgments: This research was supported in part by the Dabo Swinney All-In Foundation as well as Materials Assembly and Design Excellence in South Carolina (MADE in SC) under the National Science Foundation EPSCoR Program under NSF Award #OIA-1655740. Data presented in this material was partially collected using SC BioCRAFT facilities supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under award number P30 GM131959. Citation Format: Audreanna Miserendino, Sevrina Tekle, James Kalogeros, Angela Alexander-Bryant. Characterization of targeting peptide sequences for peptide-mediated delivery of siRNA in HER2+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7252.

Site-specific antibody-polymer conjugates for siRNA delivery.

Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA

Copolymer of Poly(Ethylene Glycol) and Poly((L)-Lysine) Grafting Polyethylenimine Through A Reducible Disulfide Linkage for Sirna Delivery

An Antibody Fragment Functionalized Dendritic PEGylated Poly(2-(Dimethylamino)ethyl Diacrylate) As a Vehicle of Exogenous Microrna.

Redox-Responsive Polymeric RNAi Based on Multivalent Conjugation of siRNA for Improved Intracellular Delivery.

Synthetic Polymer Tag for Intracellular Delivery of Sirna

Novel aromatic moieties-modified poly(glycidyl amine)s with potent siRNA delivery and cancer treatment effect

Abstract 7252: Characterization of targeting peptide sequences for peptide-mediated delivery of siRNA in HER2+ breast cancer

Polymeric RNAi Constructs Tailored with Appreciable Transcellular Trafficking Functions for Potential Suppression of Parathyroid Hormone Production

A Biodegradable Amphiphilic and Cationic Triblock Copolymer for the Delivery of Sirna Targeting the Acid Ceramidase Gene for Cancer Therapy

SiRNA-phospholipid Conjugates for Gene and Drug Delivery in Cancer Treatment.

Targeted Sirna Delivery by Anti-Her2 Antibody-Modified Nanoparticles of Mpeg-Chitosan Diblock Copolymer

Antibody Mediated in Vivo Delivery of Small Interfering RNAs Via Cell-Surface Receptors

Genetically Engineered Membrane‐Coated Nanoparticles as Versatile Platforms with Reduced Protein Corona for Targeted siRNA Delivery

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

Aptamer Mediated Delivery of Small Interfering RNAs

Aptamer-functionalized silver nanoclusters-mediated cell type-specific siRNA delivery and tracking

Quantum-dot Based Nanoparticles for Targeted Silencing of HER2/neu Gene Via RNA Interference

A ribonucleoprotein octamer for targeted siRNA delivery

Multivalent Methionine‐functionalized Biocompatible Block Copolymers for Targeted Small Interfering RNA Delivery and Subsequent Reversal Effect on Adriamycin Resistance in Human Breast Cancer Cell Line MCF‐7/ADR

Size- and Surface- Dual Engineered Small Polyplexes for Efficiently Targeting Delivery of Sirna.